Clinical trials: Recurrent Low Grade Glioma
Intracranial Neoplasm, Low Grade Glioma
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back.
- Conditions
- Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma
- Trial name
- UC-GlioFET (NCT04044937)
- Testing
- F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Thomas Hope
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioma
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in patients with recurrent high grade glioma and in patients with low grade glioma.
- Trial name
- NCT01229644
- Testing
- Crenolanib (CP-868,596)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00360854
- Testing
- erlotinib hydrochloride, mutation analysis, polymorphism analysis
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Children's Cancer and Leukaemia Group
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
The purpose of this study is to determine whether oral vinorelbine is effective in the treatment of children with progressive or recurrent unresectable low grade glioma.
- Trial name
- OVIMA-1210 (NCT02197637)
- Testing
- ORAL VINORELBINE
- Where
- 16 sites in France
- Volunteers
- 39 people
- Sponsor
- Centre Oscar Lambret
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with progressive…
- Trial name
- NCT00003466
- Testing
- temozolomide
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, etoposide phosphate, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00238173
- Testing
- filgrastim, acetylcysteine, carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical